Candesartan

證據等級: L5

預測適應症: 10 個

Candesartan: From Hypertension to Migraine Disorder

One-Sentence Summary

Candesartan is an angiotensin II type 1 (AT1) receptor blocker (ARB) widely established for the treatment of hypertension and heart failure. The TxGNN model predicts it may be effective for Migraine Disorder, with 3 directly relevant clinical trials and 20 publications currently supporting this direction — including a landmark 2025 Phase 2 RCT published in The Lancet Neurology.

Quick Overview

Item	Content
Original Indication	Hypertension / Heart failure (established ARB class indication)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.97%
Evidence Level	L2
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Candesartan is an angiotensin II type 1 (AT1) receptor blocker. By competitively antagonizing AT1 receptors, it prevents angiotensin II from exerting its vasoconstrictive and pro-inflammatory effects on the vasculature, kidney, and central nervous system. Although detailed MOA data from DrugBank was not retrievable in this Evidence Pack, the mechanistic rationale for migraine prevention is well-supported in the literature.

The link between the renin-angiotensin-aldosterone system (RAAS) and migraine pathophysiology is biologically plausible and increasingly well-characterised. AT1 receptors are expressed on trigeminovascular neurons and cerebral blood vessels. Angiotensin II sensitises the trigeminovascular system and may facilitate cortical spreading depression (CSD) — the electrophysiological event underlying migraine aura. AT1 blockade is hypothesised to reduce CSD frequency, suppress CGRP release from trigeminal fibres, and normalise cerebrovascular tone through enhanced nitric oxide (NO) signalling. Genetic studies of ACE insertion/deletion polymorphisms have further reinforced the biological plausibility of this RAAS–migraine connection.

This mechanistic rationale is now backed by a Phase 2 RCT (NCT04574713, n=450) published in The Lancet Neurology (2025), as well as an earlier head-to-head comparison with propranolol. Multiple clinical practice guidelines (AAN, ACP, Canadian Headache Society) already reference candesartan as a second-line preventive option, making this one of the most evidence-supported repurposing predictions in this dataset.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04574713	Phase 2	Completed	450	Multicenter binational RCT evaluating candesartan 8 mg and 16 mg vs placebo for episodic migraine prevention; confirms favorable efficacy seen in earlier crossover studies; primary results published in Lancet Neurology 2025 (PMID 40975098)
NCT00884663	Phase 2/3	Completed	72	Double-blind, triple crossover head-to-head comparison of candesartan vs propranolol for migraine prophylaxis; demonstrated candesartan non-inferior to the standard-of-care agent
NCT04138316	Observational	Completed	85	CandeSpartan Study — prospective real-world cohort of patients with episodic or chronic migraine who had failed ≥3 prior preventive drugs; assessed response predictors and tolerability; published in Cephalalgia 2024 (PMID 38663908)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40975098	2025	RCT (Phase 2)	The Lancet Neurology	Randomised, triple-blind, placebo-controlled trial of candesartan for episodic migraine prevention; demonstrated significant reduction in migraine days with favorable tolerability profile
39899861	2025	Clinical Practice Guideline (ACP)	Annals of Internal Medicine	American College of Physicians guideline on pharmacologic prevention of episodic migraine in outpatient adults; includes evidence review of ARBs including candesartan
38057728	2023	Systematic Review + Network Meta-analysis	Journal of Headache and Pain	Network meta-analysis ranking preventive drugs for chronic migraine in adults; provides comparative effectiveness context for candesartan vs other agents
37350141	2023	Systematic Review / Meta-analysis	Cephalalgia	Evaluated blood pressure-lowering medications including ARBs for episodic migraine prevention; assessed whether benefits extend across antihypertensive drug classes
38663908	2024	Prospective Observational Cohort	Cephalalgia	CandeSpartan Study — real-world effectiveness and tolerability of candesartan in treatment-refractory migraine patients; identifies predictors of clinical response
22529202	2012	Evidence-Based Guideline (AAN)	Neurology	AAN/American Headache Society guideline update on pharmacologic treatment for episodic migraine prevention; includes candesartan among options with emerging evidence
22683887	2012	Clinical Practice Guideline (CHS)	Canadian Journal of Neurological Sciences	Canadian Headache Society guideline for migraine prophylaxis; includes evidence-based recommendations for second-line agents including candesartan
33589682	2021	Retrospective Cohort	Scientific Reports	Real-world effectiveness and tolerability of candesartan in migraine practice (2008–2019); explores predictors of patient response with moderate external validity
40571531	2025	Scoping Review	Clinical Therapeutics	Comprehensive scoping review of candesartan for migraine headache management; summarises all available clinical evidence and contextualises its role as a preventive option
30600979	2019	Review	American Family Physician	Practical review of migraine headache prophylaxis for primary care; discusses when to initiate preventive therapy and the place of ARBs in the treatment algorithm

India Market Information

Candesartan currently has no registered products in the India market database. The drug is not marketed at this time.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No registrations found	—	—

Note: Candesartan is a well-established antihypertensive ARB available in many global markets (US, EU, Japan, Taiwan) and generics exist widely. The absence of India registration may reflect a data gap or pending regulatory status rather than unavailability of the compound globally.

Safety Considerations

Formal safety data (warnings, contraindications, and drug interaction profiles) was not retrievable for this Evidence Pack.

Please refer to the package insert for safety information.

Key known class-level safety signals for ARBs (for reference only):

Contraindicated in pregnancy (second and third trimester): Risk of fetal renal dysgenesis, oligohydramnios, and pulmonary hypoplasia — documented in case series with candesartan specifically (PMID 15669052, 18412789, 21271514)
Hyperkalemia risk: Particularly when combined with other RAAS inhibitors, potassium-sparing diuretics, or in patients with renal impairment
Renal function monitoring: Required in patients with chronic kidney disease or heart failure

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A Phase 2 multicenter RCT (NCT04574713, n=450, Lancet Neurology 2025) has now confirmed candesartan’s efficacy for episodic migraine prevention, building on an earlier crossover trial vs propranolol. Multiple international clinical guidelines (AAN, ACP, Canadian Headache Society) already reference candesartan as a second-line preventive agent. The mechanistic basis via AT1 receptor blockade in the trigeminovascular system is well-supported. Evidence level L2 is appropriate, as no completed Phase 3 trials yet exist — but the evidence base is maturing.

To proceed, the following is needed:

India regulatory pathway: Confirm whether candesartan requires new drug registration or can be listed under existing ARB category approvals; clarify current import/generic availability
Formal safety data retrieval: Download and parse the CDSCO package insert (if applicable) or reference the approved product labeling from an established market (EU/US) for full contraindication and DDI profile
Phase 3 evidence gap: Monitor whether NCT04574713’s results catalyse a Phase 3 trial; current L2 classification reflects the absence of confirmatory Phase 3 data
Subtype clarification: TxGNN also flagged migraine with brainstem aura (Rank 2) — note that standard ARB use in hemiplegic and basilar-type migraine subtypes may carry additional cardiovascular risk considerations and requires specialist neurology input before any clinical application
Dose optimisation: NCT04574713 evaluated both 8 mg and 16 mg doses; confirm which dose confers optimal efficacy-tolerability balance based on the 2025 publication findings before any protocol design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.